These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. Gene therapy for ADA-SCID, the first marketing approval of an Aiuti A; Roncarolo MG; Naldini L EMBO Mol Med; 2017 Jun; 9(6):737-740. PubMed ID: 28396566 [TBL] [Abstract][Full Text] [Related]
47. Bone marrow transplantation and alternatives for adenosine deaminase deficiency. Gaspar HB Immunol Allergy Clin North Am; 2010 May; 30(2):221-36. PubMed ID: 20493398 [TBL] [Abstract][Full Text] [Related]
48. Phoenix rising: gene therapy makes a comeback. Limberis MP Acta Biochim Biophys Sin (Shanghai); 2012 Aug; 44(8):632-40. PubMed ID: 22623503 [TBL] [Abstract][Full Text] [Related]
49. Gene therapy in the treatment of disease. Dickler HB; Collier E J Allergy Clin Immunol; 1994 Dec; 94(6 Pt 1):942-51. PubMed ID: 7798542 [No Abstract] [Full Text] [Related]
50. Recollections from a Pioneer Who Provided the Foundation for the Success of Gene Therapy in Treating Severe Combined Immune Deficiencies. Wilson JM Hum Gene Ther Clin Dev; 2016 Jun; 27(2):53-6. PubMed ID: 27314911 [No Abstract] [Full Text] [Related]
51. Good Laboratory Practice Preclinical Safety Studies for GSK2696273 (MLV Vector-Based Ex Vivo Gene Therapy for Adenosine Deaminase Deficiency Severe Combined Immunodeficiency) in NSG Mice. Carriglio N; Klapwijk J; Hernandez RJ; Vezzoli M; Chanut F; Lowe R; Draghici E; Nord M; Albertini P; Cristofori P; Richards J; Staton H; Appleby J; Aiuti A; Sauer AV Hum Gene Ther Clin Dev; 2017 Mar; 28(1):17-27. PubMed ID: 28319446 [TBL] [Abstract][Full Text] [Related]
52. At age 2, gene therapy enters a growth phase. Thompson L Science; 1992 Oct; 258(5083):744-6. PubMed ID: 1472258 [No Abstract] [Full Text] [Related]
53. Improved retroviral gene transfer into murine and Rhesus peripheral blood or bone marrow repopulating cells primed in vivo with stem cell factor and granulocyte colony-stimulating factor. Dunbar CE; Seidel NE; Doren S; Sellers S; Cline AP; Metzger ME; Agricola BA; Donahue RE; Bodine DM Proc Natl Acad Sci U S A; 1996 Oct; 93(21):11871-6. PubMed ID: 8876230 [TBL] [Abstract][Full Text] [Related]
55. Gene transfer into hematopoietic stem cells: prospects for human gene therapy. Einerhand MP; Valerio D Curr Top Microbiol Immunol; 1992; 177():217-35. PubMed ID: 1353431 [No Abstract] [Full Text] [Related]
56. Progress in genetic therapy for severe combined immunodeficiency associated with adenosine deaminase deficiency. Williams DA Mol Ther; 2009 Apr; 17(4):577-8. PubMed ID: 19337228 [No Abstract] [Full Text] [Related]
59. A small step for gene therapy. Nat Genet; 1994 Apr; 6(4):323-4. PubMed ID: 8054965 [No Abstract] [Full Text] [Related]
60. PEG-ADA: an alternative to haploidentical bone marrow transplantation and an adjunct to gene therapy for adenosine deaminase deficiency. Hershfield MS Hum Mutat; 1995; 5(2):107-12. PubMed ID: 7749407 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]